Amsacrine

Drug Profile

Amsacrine

Alternative Names: Amekrin; Amsa P-D; Amsidine; Amsidyl; CI 880; m AMSA; NSC 141549; NSC 156303; NSC 249992; SN 11841

Latest Information Update: 26 Apr 2016

Price : $50

At a glance

  • Originator Auckland Cancer Society Research Centre
  • Class Aminoacridines; Antineoplastics; Small molecules
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Leukaemia

Most Recent Events

  • 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
  • 21 Apr 2011 ProStrakan has been acquired by Kyowa Hakko Kirin
  • 31 Jan 2004 OTL Pharma has been acquired by, and merged into, Strakan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top